Mouse models of graft-versus-host disease: Advances and limitations

DMM Disease Models and Mechanisms

Volumn 4, Issue 3, 2011, Pages 318-333

  Schroeder, Mark A ^a   DiPersio, John F ^a  

^a USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FLUDARABINE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ANTIGEN SPECIFICITY; BONE MARROW TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOTOXICITY; GRAFT RECIPIENT; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCLERODERMA; WHOLE BODY RADIATION; XENOTRANSPLANTATION;

ANIMALS; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA; MICE; TRANSLATIONAL RESEARCH;

EID: 79956121863     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.006668     Document Type: Review

References (157)

1. Abdollahi, A., Li, M., Ping, G., Plathow, C., Domhan, S., Kiessling, F., Lee, L. B., McMahon, G., Grone, H. J., Lipson, K. E. et al. (2005). Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J. Exp. Med. 201, 925-935.
2. Albert, M. H., Liu, Y., Anasetti, C. and Yu, X. Z. (2005). Antigen-dependent suppression of alloresponses by Foxp3-induced regulatory T cells in transplantation. Eur. J. Immunol. 35, 2598-2607.
3. Alousi, A. M., Weisdorf, D. J., Logan, B. R., Bolanos-Meade, J., Carter, S., Difronzo, N., Pasquini, M., Goldstein, S. C., Ho, V. T., Hayes-Lattin, B. et al. (2009). Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 114, 511-517.
4. Anderson, B. E., McNiff, J. M., Jain, D., Blazar, B. R., Shlomchik, W. D. and Shlomchik, M. J. (2005). Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 105, 2227-2234. (Pubitemid 40731817)
5. Antin, J. H., Weisdorf, D., Neuberg, D., Nicklow, R., Clouthier, S., Lee, S. J., Alyea, E., McGarigle, C., Blazar, B. R., Sonis, S. et al. (2002). Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100, 3479-3482.
6. Baker, M. B., Altman, N. H., Podack, E. R. and Levy, R. B. (1996). The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J. Exp. Med. 183, 2645-2656.
7. Barnden, M. J., Allison, J., Heath, W. R. and Carbone, F. R. (1998). Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76, 34-40.
8. Barnes, D. W. and Loutit, J. F. (1957). Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br. J. Haematol. 3, 241-252.
9. Baron, C., Somogyi, R., Greller, L. D., Rineau, V., Wilkinson, P., Cho, C. R., Cameron, M. J., Kelvin, D. J., Chagnon, P., Roy, D. C. et al. (2007). Prediction of graft-versus-host disease in humans by donor gene-expression profiling. PLoS Med. 4, e23.
10. Beilhack, A., Schulz, S., Baker, J., Beilhack, G. F., Wieland, C. B., Herman, E. I., Baker, E. M., Cao, Y. A., Contag, C. H. and Negrin, R. S. (2005). In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 106, 1113-1122.
11. Bennett, M., Taylor, P. A., Austin, M., Baker, M. B., Schook, L. B., Rutherford, M., Kumar, V., Podack, E. R., Mohler, K. M., Levy, R. B. et al. (1998). Cytokine and cytotoxic pathways of NK cell rejection of class I-deficient bone marrow grafts: influence of mouse colony environment. Int. Immunol. 10, 785-790.
12. Berger, M., Wettstein, P. J. and Korngold, R. (1994). T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens. Transplantation 57, 1095-1102. (Pubitemid 24127699)
13. Blaser, B. W., Roychowdhury, S., Kim, D. J., Schwind, N. R., Bhatt, D., Yuan, W., Kusewitt, D. F., Ferketich, A. K., Caligiuri, M. A. and Guimond, M. (2005). Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease. Blood 105, 894-901. (Pubitemid 40070781)
14. Blazar, B. R., Carroll, S. F. and Vallera, D. A. (1991). Prevention of murine graft-versus-host disease and bone marrow alloengraftment across the major histocompatibility barrier after donor graft preincubation with anti-LFA1 immunotoxin. Blood 78, 3093-3102.
15. Bleakley, M. and Riddell, S. R. (2004). Molecules and mechanisms of the graft-versus-leukaemia effect. Nat. Rev. Cancer 4, 371-380.
16. Bonomo, A., Kehn, P. J., Payer, E., Rizzo, L., Cheever, A. W. and Shevach, E. M. (1995). Pathogenesis of post-thymectomy autoimmunity. Role of syngeneic MLR-reactive T cells. J. Immunol. 154, 6602-6611.
17. Braun, M. Y., Lowin, B., French, L., Acha-Orbea, H. and Tschopp, J. (1996). Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183, 657-661.
18. Brok, H. P., Vossen, J. M. and Heidt, P. J. (1998). IFN-gamma-mediated prevention of graft-versus-host disease: pharmacodynamic studies and influence on proliferative capacity of chimeric spleen cells. Bone Marrow Transplant. 22, 1005-1010.
19. Brown, G. R., Lee, E. and Thiele, D. L. (2002). TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J->C57BL/6J x bm12)F1 mice. J. Immunol. 168, 3065-3071.
20. Cao, T. M., Lo, B., Ranheim, E. A., Grumet, F. C. and Shizuru, J. A. (2003). Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice. Proc. Natl. Acad. Sci. USA 100, 11571-11576.
21. Carlson, M. J., West, M. L., Coghill, J. M., Panoskaltsis-Mortari, A., Blazar, B. R. and Serody, J. S. (2009). In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 113, 1365-1374.
22. Chen, X., Vodanovic-Jankovic, S., Johnson, B., Keller, M., Komorowski, R. and Drobyski, W. R. (2007). Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood 110, 3804-3813.
23. Choi, J., Ritchey, J., Prior, J. L., Holt, M., Shannon, W. D., Deych, E., Piwnica-Worms, D. R. and DiPersio, J. F. (2010). In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 116, 129-139.
24. Christianson, S. W., Greiner, D. L., Hesselton, R. A., Leif, J. H., Wagar, E. J., Schweitzer, I. B., Rajan, T. V., Gott, B., Roopenian, D. C. and Shultz, L. D. (1997). Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NODscid mice. J. Immunol. 158, 3578-3586.
25. Chu, Y. W. and Gress, R. E. (2008). Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol. Blood Marrow Transplant. 14, 365-378.
26. Claman, H. N., Jaffee, B. D., Huff, J. C. and Clark, R. A. (1985). Chronic graft-versushost disease as a model for scleroderma. II. Mast cell depletion with deposition of immunoglobulins in the skin and fibrosis. Cell. Immunol. 94, 73-84.
27. Cooke, K. R., Kobzik, L., Martin, T. R., Brewer, J., Delmonte, J., Jr, Crawford, J. M. and Ferrara, J. L. (1996). An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 88, 3230-3239.
28. Cooke, K. R., Hill, G. R., Crawford, J. M., Bungard, D., Brinson, Y. S., Delmonte, J., Jr and Ferrara, J. L. (1998). Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J. Clin. Invest. 102, 1882-1891.
29. Cutler, C., Miklos, D., Kim, H. T., Treister, N., Woo, S. B., Bienfang, D., Klickstein, L. B., Levin, J., Miller, K., Reynolds, C. et al. (2006). Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108, 756-762.
30. Damdinsuren, B., Zhang, Y., Khalil, A., Wood, W. H., 3rd, Becker, K. G., Shlomchik, M. J. and Sen, R. (2010). Single round of antigen receptor signaling programs naive B cells to receive T cell help. Immunity 32, 355-366.
31. Daniels, C. E., Wilkes, M. C., Edens, M., Kottom, T. J., Murphy, S. J., Limper, A. H. and Leof, E. B. (2004). Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. 114, 1308-1316.
32. De Wit, D., Van Mechelen, M., Zanin, C., Doutrelepont, J. M., Velu, T., Gerard, C., Abramowicz, D., Scheerlinck, J. P., De Baetselier, P., Urbain, J. et al. (1993). Preferential activation of Th2 cells in chronic graft-versus-host reaction. J. Immunol. 150, 361-366.
33. DeClerck, Y., Draper, V. and Parkman, R. (1986). Clonal analysis of murine graft-vs-host disease. II. Leukokines that stimulate fibroblast proliferation and collagen synthesis in graft-vs. host disease. J. Immunol. 136, 3549-3552.
34. Durie, F. H., Aruffo, A., Ledbetter, J., Crassi, K. M., Green, W. R., Fast, L. D. and Noelle, R. J. (1994). Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease. J. Clin. Invest. 94, 1333-1338.
35. Edinger, M., Hoffmann, P., Ermann, J., Drago, K., Fathman, C. G., Strober, S. and Negrin, R. S. (2003). CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9, 1144-1150.
36. Eyrich, M., Burger, G., Marquardt, K., Budach, W., Schilbach, K., Niethammer, D. and Schlegel, P. G. (2005). Sequential expression of adhesion and costimulatory molecules in graft-versus-host disease target organs after murine bone marrow transplantation across minor histocompatibility antigen barriers. Biol. Blood Marrow Transplant. 11, 371-382.
37. Fanning, S. L., Appel, M. Y., Berger, S. A., Korngold, R. and Friedman, T. M. (2009). The immunological impact of genetic drift in the B10.BR congenic inbred mouse strain. J. Immunol. 183, 4261-4272.
38. Ferrara, J. L., Abhyankar, S. and Gilliland, D. G. (1993). Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1. Transplant. Proc. 25, 1216-1217.
39. Ferrara, J. L., Levine, J. E., Reddy, P. and Holler, E. (2009). Graft-versus-host disease. Lancet 373, 1550-1561.
40. Fowler, D. H., Breglio, J., Nagel, G., Eckhaus, M. A. and Gress, R. E. (1996). Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease. J. Immunol. 157, 4811-4821.
41. Fujiwara, K., Sakaguchi, N. and Watanabe, T. (1991). Sialoadenitis in experimental graft-versus-host disease. An animal model of Sjogren's syndrome. Lab. Invest. 65, 710-718.
42. Fukushi, N., Arase, H., Wang, B., Ogasawara, K., Gotohda, T., Good, R. A. and Onoe, K. (1990). Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance. Proc. Natl. Acad. Sci. USA 87, 6301-6305.
43. Gendelman, M., Hecht, T., Logan, B., Vodanovic-Jankovic, S., Komorowski, R. and Drobyski, W. R. (2004). Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease. J. Immunol. 172, 3328-3336.
44. Gerbitz, A., Schultz, M., Wilke, A., Linde, H. J., Scholmerich, J., Andreesen, R. and Holler, E. (2004). Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. Blood 103, 4365-4367.
45. Ghayur, T., Seemayer, T. A., Xenocostas, A. and Lapp, W. S. (1988). Complete sequential regeneration of graft-vs.-host-induced severely dysplastic thymuses. Implications for the pathogenesis of chronic graft-vs.-host disease. Am. J. Pathol. 133, 39-46.
46. Gorski, J., Chen, X., Gendelman, M., Yassai, M., Krueger, A., Tivol, E., Logan, B., Komorowski, R., Vodanovic-Jankovic, S. and Drobyski, W. R. (2007). Homeostatic expansion and repertoire regeneration of donor T cells during graft versus host disease is constrained by the host environment. Blood 109, 5502-5510.
47. Graubert, T. A., DiPersio, J. F., Russell, J. H. and Ley, T. J. (1997). Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J. Clin. Invest. 100, 904-911.
48. Grubin, C. E., Kovats, S., deRoos, P. and Rudensky, A. Y. (1997). Deficient positive selection of CD4 T cells in mice displaying altered repertoires of MHC class II-bound self-peptides. Immunity 7, 197-208.
49. Hakim, F. T., Sharrow, S. O., Payne, S. and Shearer, G. M. (1991). Repopulation of host lymphohematopoietic systems by donor cells during graft-versus-host reaction in unirradiated adult F1 mice injected with parental lymphocytes. J. Immunol. 146, 2108-2115.
50. Hamilton, B. L. (1987). L3T4-positive T cells participate in the induction of graft-vs-host disease in response to minor histocompatibility antigens. J. Immunol. 139, 2511-2515.
51. Hamilton, B. L. and Parkman, R. (1983). Acute and chronic graft-versus-host disease induced by minor histocompatibility antigens in mice. Transplantation 36, 150-155.
52. Hauri-Hohl, M. M., Keller, M. P., Gill, J., Hafen, K., Pachlatko, E., Boulay, T., Peter, A., Hollander, G. A. and Krenger, W. (2007). Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation. Blood 109, 4080-4088.
53. Hildebrandt, G. C., Olkiewicz, K. M., Corrion, L. A., Chang, Y., Clouthier, S. G., Liu, C. and Cooke, K. R. (2004). Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation. Blood 104, 586-593.
54. Hill, G. R., Crawford, J. M., Cooke, K. R., Brinson, Y. S., Pan, L. and Ferrara, J. L. (1997). Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90, 3204-3213.
55. Hoffmann-Fezer, G., Gall, C., Zengerle, U., Kranz, B. and Thierfelder, S. (1993). Immunohistology and immunocytology of human T-cell chimerism and graft-versus-host disease in SCID mice. Blood 81, 3440-3448.
56. Hori, T., Naishiro, Y., Sohma, H., Suzuki, N., Hatakeyama, N., Yamamoto, M., Sonoda, T., Mizue, Y., Imai, K., Tsutsumi, H. et al. (2008). CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood 111, 4403-4412.
57. Howell, C. D., Yoder, T., Claman, H. N. and Vierling, J. M. (1989). Hepatic homing of mononuclear inflammatory cells isolated during murine chronic graft-vs-host disease. J. Immunol. 143, 476-483.
58. Iclozan, C., Yu, Y., Liu, C., Liang, Y., Yi, T., Anasetti, C. and Yu, X. Z. (2009). T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol. Blood Marrow Transplant. 16, 170-178.
59. Ito, R., Katano, I., Kawai, K., Hirata, H., Ogura, T., Kamisako, T., Eto, T. and Ito, M. (2009). Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation 87, 1654-1658.
60. Ito, S., Ueno, M., Nishi, S., Arakawa, M., Ikarashi, Y., Saitoh, T. and Fujiwara, M. (1992). Histological characteristics of lupus nephritis in F1 mice with chronic graft-versus-host reaction across MHC class II difference. Autoimmunity 12, 79-87.
61. Jaffee, B. D. and Claman, H. N. (1983). Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell. Immunol. 77, 1-12.
62. Jiang, Z., Podack, E. and Levy, R. B. (2001). Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis. Blood 98, 390-397.
63. Kanamaru, A., Okamoto, T., Matsuda, K., Hara, H. and Nagai, K. (1984). Elevation of erythroid colony-stimulating activity in the serum of mice with graft-versus-host disease. Exp. Hematol. 12, 763-767.
64. Kaplan, D. H., Anderson, B. E., McNiff, J. M., Jain, D., Shlomchik, M. J. and Shlomchik, W. D. (2004). Target antigens determine graft-versus-host disease phenotype. J. Immunol. 173, 5467-5475.
65. Kappel, L. W., Goldberg, G. L., King, C. G., Suh, D. Y., Smith, O. M., Ligh, C., Holland, A. M., Grubin, J., Mark, N. M., Liu, C. et al. (2009). IL-17 contributes to CD4-mediated graft-versus-host disease. Blood 113, 945-952.
66. Kim, J., Kim, H. J., Choi, W. S., Nam, S. H., Cho, H. R. and Kwon, B. (2006). Maintenance of CD8+ T-cell anergy by CD4+CD25+ regulatory T cells in chronic graft-versus-host disease. Exp. Mol. Med. 38, 494-501.
67. Kim, J., Park, K., Kim, H. J., Kim, H. A., Jung, D., Choi, H. J., Choi, S. Y., Seo, K. W., Cho, H. R. and Kwon, B. (2008). Breaking of CD8+ T cell tolerance through in vivo ligation of CD40 results in inhibition of chronic graft-versus-host disease and complete donor cell engraftment. J. Immunol. 181, 7380-7389.
68. Kim, Y. M., Sachs, T., Asavaroengchai, W., Bronson, R. and Sykes, M. (2003). Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J. Clin. Invest. 111, 659-669.
69. King, M. A., Covassin, L., Brehm, M. A., Racki, W., Pearson, T., Leif, J., Laning, J., Fodor, W., Foreman, O., Burzenski, L. et al. (2009). Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin. Exp. Immunol. 157, 104-118.
70. Kisielow, P., Bluthmann, H., Staerz, U. D., Steinmetz, M. and von Boehmer, H. (1988). Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature 333, 742-746.
71. Kolb, H. J. (2008). Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112, 4371-4383.
72. Kolb, H. J., Schmid, C., Barrett, A. J. and Schendel, D. J. (2004). Graft-versus-leukemia reactions in allogeneic chimeras. Blood 103, 767-776.
73. Korngold, R. (1992). Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses. Bone Marrow Transplant. 9, 355-364.
74. Korngold, R. and Sprent, J. (1978). Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J. Exp. Med. 148, 1687-1698.
75. Korngold, R. and Sprent, J. (1987). Variable capacity of L3T4+ T cells to cause lethal graft-versus-host disease across minor histocompatibility barriers in mice. J. Exp. Med. 165, 1552-1564.
76. Krenger, W. and Hollander, G. A. (2008). The immunopathology of thymic GVHD. Semin. Immunopathol. 30, 439-456.
77. Krenger, W., Rossi, S. and Hollander, G. A. (2000a). Apoptosis of thymocytes during acute graft-versus-host disease is independent of glucocorticoids. Transplantation 69, 2190-2193.
78. Krenger, W., Rossi, S., Piali, L. and Hollander, G. A. (2000b). Thymic atrophy in murine acute graft-versus-host disease is effected by impaired cell cycle progression of host pro-T and pre-T cells. Blood 96, 347-354.
79. Lee, S. J. (2010). Have we made progress in the management of chronic graft-vs-host disease? Best Pract. Res Clin. Haematol. 23, 529-535.
80. Levi-Schaffer, F. and Weg, V. B. (1997). Mast cells, eosinophils and fibrosis. Clin. Exp. Allergy 27 Suppl. 1, 64-70.
81. Levy, S., Nagler, A., Okon, S. and Marmary, Y. (2000). Parotid salivary gland dysfunction in chronic graft-versus-host disease (cGVHD): a longitudinal study in a mouse model. Bone Marrow Transplant. 25, 1073-1078.
82. Liang, Y., Liu, C., Djeu, J. Y., Zhong, B., Peters, T., Scharffetter-Kochanek, K., Anasetti, C. and Yu, X. Z. (2008). Beta2 integrins separate graft-versus-host disease and graft-versus-leukemia effects. Blood 111, 954-962.
83. Lu, Y. and Waller, E. K. (2009). Dichotomous role of interferon-gamma in allogeneic bone marrow transplant. Biol. Blood Marrow Transplant. 15, 1347-1353.
84. Lucas, P. J., Shearer, G. M., Neudorf, S. and Gress, R. E. (1990). The human antimurine xenogeneic cytotoxic response. I. Dependence on responder antigen-presenting cells. J. Immunol. 144, 4548-4554.
85. Mabed, M., Maroof, S., Zalta, K. and El-Awadee, M. (2005). Delayed or delayed sequential bone marrow transplantation: relevance for acute graft-versus-host disease prevention after major H2 incompatible transplantation. Bone Marrow Transplant. 35, 803-806.
86. Maeda, Y., Levy, R. B., Reddy, P., Liu, C., Clouthier, S. G., Teshima, T. and Ferrara, J. L. (2005). Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood 105, 2023-2027.
87. Mapara, M. Y., Leng, C., Kim, Y. M., Bronson, R., Lokshin, A., Luster, A. and Sykes, M. (2006). Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. Biol. Blood Marrow Transplant. 12, 623-634.
88. Mathis, D. and Benoist, C. (2009). Aire. Annu. Rev. Immunol. 27, 287-312.
89. McCormick, L. L., Zhang, Y., Tootell, E. and Gilliam, A. C. (1999). Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J. Immunol. 163, 5693-5699.
90. Mestas, J. and Hughes, C. C. (2004). Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731-2738.
91. Morris, S. C., Cheek, R. L., Cohen, P. L. and Eisenberg, R. A. (1990a). Allotype-specific immunoregulation of autoantibody production by host B cells in chronic graft-versus host disease. J. Immunol. 144, 916-922.
92. Morris, S. C., Cheek, R. L., Cohen, P. L. and Eisenberg, R. A. (1990b). Autoantibodies in chronic graft versus host result from cognate T-B interactions. J. Exp. Med. 171, 503-517.
93. Mosier, D. E., Gulizia, R. J., Baird, S. M. and Wilson, D. B. (1988). Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335, 256-259.
94. Murphy, K. M., Heimberger, A. B. and Loh, D. Y. (1990). Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 250, 1720-1723.
95. Negrin, R. S. and Contag, C. H. (2006). In vivo imaging using bioluminescence: a tool for probing graft-versus-host disease. Nat. Rev. Immunol. 6, 484-490.
96. Nervi, B., Rettig, M. P., Ritchey, J. K., Wang, H. L., Bauer, G., Walker, J., Bonyhadi, M. L., Berenson, R. J., Prior, J. L., Piwnica-Worms, D. et al. (2007). Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice. Exp. Hematol. 35, 1823-1838.
97. Nestel, F. P., Price, K. S., Seemayer, T. A. and Lapp, W. S. (1992). Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J. Exp. Med. 175, 405-413.
98. Niculescu, F., Niculescu, T., Nguyen, P., Puliaev, R., Papadimitriou, J. C., Gaspari, A., Rus, H. and Via, C. S. (2005). Both apoptosis and complement membrane attack complex deposition are major features of murine acute graft-vs.-host disease. Exp. Mol. Pathol. 79, 136-145.
99. Nikolic, B., Lee, S., Bronson, R. T., Grusby, M. J. and Sykes, M. (2000). Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J. Clin. Invest. 105, 1289-1298.
100. Nishimura, R., Baker, J., Beilhack, A., Zeiser, R., Olson, J. A., Sega, E. I., Karimi, M. and Negrin, R. S. (2008). In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 112, 2563-2574.
101. Nishizuka, Y. and Sakakura, T. (1969). Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 166, 753-755.
102. Ordemann, R., Hutchinson, R., Friedman, J., Burakoff, S. J., Reddy, P., Duffner, U., Braun, T. M., Liu, C., Teshima, T. and Ferrara, J. L. (2002). Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versushost disease. J. Clin. Invest. 109, 1249-1256.
103. Paczesny, S., Krijanovski, O. I., Braun, T. M., Choi, S. W., Clouthier, S. G., Kuick, R., Misek, D. E., Cooke, K. R., Kitko, C. L., Weyand, A. et al. (2009). A biomarker panel for acute graft-versus-host disease. Blood 113, 273-278.
104. Pals, S. T., Radaszkiewicz, T., Roozendaal, L. and Gleichmann, E. (1985). Chronic progressive polyarthritis and other symptoms of collagen vascular disease induced by graft-vs-host reaction. J. Immunol. 134, 1475-1482.
105. Panoskaltsis-Mortari, A., Lacey, D. L., Vallera, D. A. and Blazar, B. R. (1998). Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 92, 3960-3967.
106. Panoskaltsis-Mortari, A., Price, A., Hermanson, J. R., Taras, E., Lees, C., Serody, J. S. and Blazar, B. R. (2004). In vivo imaging of graft-versus-host-disease in mice. Blood 103, 3590-3598.
107. Pickel, K. and Hoffmann, M. K. (1977). Suppressor T cells arising in mice undergoing a graft-vs-host response. J. Immunol. 118, 653-656.
108. Ringden, O., Karlsson, H., Olsson, R., Omazic, B. and Uhlin, M. (2009). The allogeneic graft-versus-cancer effect. Br. J. Haematol. 147, 614-633.
109. Rolink, A. G. and Gleichmann, E. (1983). Allosuppressor- and allohelper-T cells in acute and chronic graft-vs.-host (GVH) disease. III. Different Lyt subsets of donor T cells induce different pathological syndromes. J. Exp. Med. 158, 546-558.
110. Rolink, A. G., Pals, S. T. and Gleichmann, E. (1983). Allosuppressor and allohelper T cells in acute and chronic graft-vs.-host disease. II. F1 recipients carrying mutations at H-2K and/or I-A. J. Exp. Med. 157, 755-771.
111. Ruzek, M. C., Jha, S., Ledbetter, S., Richards, S. M. and Garman, R. D. (2004). A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum. 50, 1319-1331.
112. Sadeghi, B., Aghdami, N., Hassan, Z., Forouzanfar, M., Rozell, B., Abedi-Valugerdi, M. and Hassan, M. (2008). GVHD after chemotherapy conditioning in allogeneic transplanted mice. Bone Marrow Transplant. 42, 807-818.
113. Sakaguchi, S., Ono, M., Setoguchi, R., Yagi, H., Hori, S., Fehervari, Z., Shimizu, J., Takahashi, T. and Nomura, T. (2006). Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212, 8-27.
114. Sakoda, Y., Hashimoto, D., Asakura, S., Takeuchi, K., Harada, M., Tanimoto, M. and Teshima, T. (2007). Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood 109, 1756-1764.
115. Schwarte, S. and Hoffmann, M. W. (2005). Influence of radiation protocols on graft-vs-host disease incidence after bone-marrow transplantation in experimental models. Methods Mol. Med. 109, 445-458.
116. Schwarte, S., Bremer, M., Fruehauf, J., Sorge, Y., Skubich, S. and Hoffmann, M. W. (2007). Radiation protocols determine acute graft-versus-host disease incidence after allogeneic bone marrow transplantation in murine models. Int. J. Radiat. Biol. 83, 625-636.
117. Sha, W. C., Nelson, C. A., Newberry, R. D., Kranz, D. M., Russell, J. H. and Loh, D. Y. (1988). Positive and negative selection of an antigen receptor on T cells in transgenic mice. Nature 336, 73-76.
118. Shimabukuro-Vornhagen, A., Hallek, M. J., Storb, R. F. and von Bergwelt-Baildon, M. S. (2009). The role of B Cells in the pathogenesis of graft-versus-host disease. Blood 114, 4919-4927.
119. Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J. and Emerson, S. G. (1999). Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285, 412-415.
120. Skert, C., Patriarca, F., Sperotto, A., Cerno, M., Fili, C., Zaja, F., Stocchi, R., Geromin, A., Damiani, D. and Fanin, R. (2006). Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica 91, 258-261.
121. Slayback, D. L., Dobkins, J. A., Harper, J. M. and Allen, R. D. (2000). Genetic factors influencing the development of chronic graft-versus-host disease in a murine model. Bone Marrow Transplant. 26, 931-938.
122. Socié, G. and Blazar, B. R. (2009). Acute graft-versus-host disease; from the bench to the bedside. Blood 114, 4327-4336.
123. Sprent, J., Schaefer, M., Lo, D. and Korngold, R. (1986). Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences. J. Exp. Med. 163, 998-1011.
124. Sprent, J., Schaefer, M., Gao, E. K. and Korngold, R. (1988). Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. I. L3T4+ cells can either augment or retard GVHD elicited by Lyt-2+ cells in class I different hosts. J. Exp. Med. 167, 556-569.
125. Sprent, J., Schaefer, M. and Korngold, R. (1990). Role of T cell subsets in lethal graft-versus-host disease (GVHD) directed to class I versus class II H-2 differences. II. Protective effects of L3T4+ cells in anti-class II GVHD. J. Immunol. 144, 2946-2954.
126. Sun, K., Welniak, L. A., Panoskaltsis-Mortari, A., O'Shaughnessy, M. J., Liu, H., Barao, I., Riordan, W., Sitcheran, R., Wysocki, C., Serody, J. S. et al. (2004). Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc. Natl. Acad. Sci. USA 101, 8120-8125.
127. Sun, K., Wilkins, D. E., Anver, M. R., Sayers, T. J., Panoskaltsis-Mortari, A., Blazar, B. R., Welniak, L. A. and Murphy, W. J. (2005). Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 106, 3293-3299.
128. Svegliati, S., Olivieri, A., Campelli, N., Luchetti, M., Poloni, A., Trappolini, S., Moroncini, G., Bacigalupo, A., Leoni, P., Avvedimento, E. V. et al. (2007). Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110, 237-241.
129. Tawara, I., Maeda, Y., Sun, Y., Lowler, K. P., Liu, C., Toubai, T., McKenzie, A. N. and Reddy, P. (2008). Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. Exp. Hematol. 36, 988-996.
130. Teshima, T., Ordemann, R., Reddy, P., Gagin, S., Liu, C., Cooke, K. R. and Ferrara, J. L. (2002). Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat. Med. 8, 575-581.
131. Tivol, E., Komorowski, R. and Drobyski, W. R. (2005). Emergent autoimmunity in graft-versus-host disease. Blood 105, 4885-4891.
132. Tschetter, J. R., Mozes, E. and Shearer, G. M. (2000). Progression from acute to chronic disease in a murine parent-into-F1 model of graft-versus-host disease. J. Immunol. 165, 5987-5994.
133. Uberti, J. P., Ayash, L., Ratanatharathorn, V., Silver, S., Reynolds, C., Becker, M., Reddy, P., Cooke, K. R., Yanik, G., Whitfield, J. et al. (2005). Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol. Blood Marrow Transplant. 11, 680-687.
134. Vallera, D. A., Soderling, C. C., Carlson, G. J. and Kersey, J. H. (1981). Bone marrow transplantation across major histocompatibility barriers in mice. Effect of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus complement or antibody alone. Transplantation 31, 218-222.
135. van den Brink, M. R., Moore, E., Ferrara, J. L. and Burakoff, S. J. (2000). Graft-versus-host-disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity. Transplantation 69, 446-449.
136. van Leeuwen, L., Guiffre, A., Atkinson, K., Rainer, S. P. and Sewell, W. A. (2002). A two-phase pathogenesis of graft-versus-host disease in mice. Bone Marrow Transplant. 29, 151-158.
137. van Rijn, R. S., Simonetti, E. R., Hagenbeek, A., Hogenes, M. C., de Weger, R. A., Canninga-van Dijk, M. R., Weijer, K., Spits, H., Storm, G., van Bloois, L. et al. (2003). A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood 102, 2522-2531.
138. Via, C. S., Sharrow, S. O. and Shearer, G. M. (1987). Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease. J. Immunol. 139, 1840-1849.
139. Via, C. S., Rus, V., Gately, M. K. and Finkelman, F. D. (1994). IL-12 stimulates the development of acute graft-versus-host disease in mice that normally would develop chronic, autoimmune graft-versus-host disease. J. Immunol. 153, 4040-4047.
140. Via, C. S., Rus, V., Nguyen, P., Linsley, P. and Gause, W. C. (1996a). Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J. Immunol. 157, 4258-4267.
141. Via, C. S., Nguyen, P., Shustov, A., Drappa, J. and Elkon, K. B. (1996b). A major role for the Fas pathway in acute graft-versus-host disease. J. Immunol. 157, 5387-5393.
142. Vidal, S., Labrador, M., Rodriguez-Sanchez, J. L. and Gelpi, C. (1996). The role of BALB/c donor CD8+ lymphocytes in graft-versus-host disease in (BALB/c x A/J)F1 (CAF1) mice. J. Immunol. 156, 997-1005.
143. Wang, X., Roopenian, D., Martone, C., Li, N., Li, H. and Shlomchik, W. D. (2009). Mechanisms of cross-presentation in graft-vs-host disease. Blood 114, (ASH Annual Meeting Abstracts), Abstract 687.
144. Watanabe, N., Wang, Y. H., Lee, H. K., Ito, T., Cao, W. and Liu, Y. J. (2005). Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 436, 1181-1185.
145. Weiss, L., Morecki, S., Vitetta, E. S. and Slavin, S. (1983). Suppression and elimination of BCL1 leukemia by allogeneic bone marrow transplantation. J. Immunol. 130, 2452-2455.
146. Westervelt, P., Lane, A. A., Pollock, J. L., Oldfather, K., Holt, M. S., Zimonjic, D. B., Popescu, N. C., DiPersio, J. F. and Ley, T. J. (2003). High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood 102, 1857-1865.
147. Wilkinson, K. N., Anderson, B., McNiff, J., Demetris, A. J., Shlomchik, W. D. and Shlomchik, M. (2009). A new TCR transgenic model of GVHD reveals that, independent of repertoire, effector memory T cells are severely limited, and central memory T cells somewhat limited, in their ability to cause GVHD. Blood 114 (ASH Annual Meeting Abstracts), Abstract 233.
148. Wynn, T. A. (2004). Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 4, 583-594.
149. Wysocki, C. A., Panoskaltsis-Mortari, A., Blazar, B. R. and Serody, J. S. (2005). Leukocyte migration and graft-versus-host disease. Blood 105, 4191-4199.
150. Yi, T., Zhao, D., Lin, C. L., Zhang, C., Chen, Y., Todorov, I., LeBon, T., Kandeel, F., Forman, S. and Zeng, D. (2008). Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 112, 2101-2110.
151. Yu, X. Z., Albert, M. H. and Anasetti, C. (2006). Alloantigen affinity and CD4 help determine severity of graft-versus-host disease mediated by CD8 donor T cells. J. Immunol. 176, 3383-3390.
152. Zhang, C., Todorov, I., Zhang, Z., Liu, Y., Kandeel, F., Forman, S., Strober, S. and Zeng, D. (2006). Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 107, 2993-3001.
153. Zhang, Y., Joe, G., Hexner, E., Zhu, J. and Emerson, S. G. (2005). Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. J. Immunol. 174, 3051-3058.
154. Zhang, Y., Hexner, E., Frank, D. and Emerson, S. G. (2007). CD4+ T cells generated de novo from donor hemopoietic stem cells mediate the evolution from acute to chronic graft-versus-host disease. J. Immunol. 179, 3305-3314.
155. Zhao, D., Young, J. S., Chen, Y. H., Shen, E., Yi, T., Todorov, I., Chu, P. G., Forman, S. J. and Zeng, D. (2010). Alloimmune response results in expansion of autoreactive donor CD4+ T cells in transplants that can mediate chronic graft-versus-host disease. J. Immunol. 186, 856-868.
156. Zheng, H., Matte-Martone, C., Jain, D., McNiff, J. and Shlomchik, W. D. (2009). Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia. J. Immunol. 182, 5938-5948.
157. Zhou, L., Askew, D., Wu, C. and Gilliam, A. C. (2007). Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J. Invest. Dermatol. 127, 281-292.